Frontlight ResearchEarly access
Taking people in United StatesPhase 2/3
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
Key facts
- Who runs it
- Vertex Pharmaceuticals Incorporated
- Where
- Arvada, Boise, Columbus, Edina, El Paso, Gastonia, Greenville, Hinsdale, Houston, Indianapolis, Las Vegas, Lawrenceville, Los Angeles, Miami, Montgomery, New York, Orlando, Roseville, Sacramento, Salt Lake City, San Antonio, Shreveport, Spartanburg, Surprise, Tarzana, Wauwatosa, and Winter Park, United StatesSee the 28 sitesAlso in 13 other countries, 89 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 176 people, planned
- Started
- 30 Sept 2025
- Expected to end
- 29 Dec 2028
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Povetacicept
- Tacrolimus
- Record updated
- 30 October 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility
Who cannot take part
- Hypersensitivity to investigational medicinal product or to any of its excipients; Other protocol defined Inclusion/Exclusion criteria will apply
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
Also in 13 other countries, 89 sites
- Western Nephrology & Metabolic Bone Disease, PCArvada, United StatesTaking people
- CARE Institute - Boise KidneyBoise, United StatesTaking people
- DaVita Clinical Research ColumbusColumbus, United StatesTaking people
- DaVita Clinical Research EdinaEdina, United StatesTaking people
- El Paso Kidney SpecialistsEl Paso, United StatesTaking people
- Metrolina Nephrology Associates, PAGastonia, United StatesTaking people
- Carolina Nephrology GreenvilleGreenville, United StatesTaking people
- NANI ResearchHinsdale, United StatesTaking people
- DaVita Clinical Research HoustonHouston, United StatesTaking people
- Provecta Research NetworkHouston, United StatesTaking people
- Nephrology Associates of Northern Illinois and Indiana (NANI) - Indianapolis SouthIndianapolis, United StatesTaking people
- Kidney Specialists of Southern NevadaLas Vegas, United StatesTaking people
- Georgia NephrologyLawrenceville, United StatesTaking people
- Academic Medical Research Institute (AMRI)Los Angeles, United StatesTaking people
- Bioresearch PartnerMiami, United StatesTaking people
- Renal AssociatesMontgomery, United StatesTaking people
- NYU Medical CenterNew York, United StatesTaking people
- CTR Oakwater, LLCOrlando, United StatesTaking people
- St. Clair Nephrology ResearchRoseville, United StatesTaking people
- Kaiser Permanente Sacramento Medical CenterSacramento, United StatesTaking people
- Utah Kidney ResearchSalt Lake City, United StatesTaking people
- DaVita Clinical Research San AntonioSan Antonio, United StatesTaking people
- Northwest Louisiana Nephrology, LLC - ShreveportShreveport, United StatesTaking people
- Carolina Nephrology, PASpartanburg, United StatesTaking people
- Southwest Kidney Institute, PLC (SKI) - SurpriseSurprise, United StatesTaking people
- Valiance Clinical Research - Internal MedicineTarzana, United StatesTaking people
- Milwaukee Neprologists, SCWauwatosa, United StatesTaking people
- Clinical Site Partners, LLC - OrlandoWinter Park, United StatesTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).
The 3 groups in the trial
- Phase 2b: PovetaciceptTreatment being tested
Participants will be randomized to receive one of the two doses of Povetacicept.
Treatment: Povetacicept
- Phase 3: PovetaciceptTreatment being tested
Participants will be randomized to receive one of the two doses of Povetacicept (dose selected based on Phase 2b).
Treatment: Povetacicept
- Phase 3: Calcineurin Inhibitor (CNI)Existing treatment, for comparison
Participants will be randomized to receive the calcineurin inhibitor (CNI) Tacrolimus.
Treatment: Tacrolimus
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
- Fit questions
- Built from NCT07204275, who can take part
- Record updated
- 30 October 2026